General
Preferred name
EDROPHONIUM
Synonyms
EDROPHONIUM CHLORIDE ()
Edrophonium (chloride) ()
Edrophone Chloride ()
Edrophonium Chloride Preservative Free ()
Reversol ()
Camsilon ()
Enlon ()
Antirex ()
Tensilon Preservative Free ()
Edrophonii chloridum ()
Tensilon ()
NSC-759577 ()
ENLON-PLUS ()
Edrophonium cation ()
Edrophonium ion ()
P&D ID
PD009595
CAS
116-38-1
312-48-1
Tags
available
drug
Approved by
FDA
First approval
1951
Drug Status
approved
Drug indication
Myasthenia gravis
Diagnostic Aid (myasthenia gravis)
Antidote (to curare principles)
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ROE Edrophonium is primarily renally excreted with 67% of the dose appearing in the urine.; Hepatic metabolism and biliary excretion have also been demonstrated in animals
DESCRIPTION Edrophonium is the parent molecule of the clinically used rapid-onset, short-acting cholinesterase inhibitor edrophonium chloride (PubChem CID 8307). (GtoPdb)
DESCRIPTION Acetylcholinesterase inhibitor (LOPAC library)
DESCRIPTION Edrophonium chloride is a reversible Acetylcholinesterase inhibitor which is effective in avoiding the decomposition of the neurotransmitter acetylcholine competitively so that could be commonly used in the diagnosis of myasthenia gravis and other sorts o (BOC Sciences Bioactive Compounds)
DESCRIPTION Edrophonium is a reversible Acetylcholinesterase inhibitor which is effective in avoiding the decomposition of the neurotransmitter acetylcholine competitively so that could be commonly used in the diagnosis of myasthenia gravis and other sorts of disease (BOC Sciences Bioactive Compounds)
Compound Sets
24
BOC Sciences Bioactive Compounds
edrophonium-chloride-cas-116-38-1-item-55149
edrophonium-cas-312-48-1-item-474365
Cayman Chemical Bioactives
15928
ChEMBL Approved Drugs
CHEMBL1128
CHEMBL1104
ChEMBL Drugs
CHEMBL1128
CHEMBL1104
Drug Repurposing Hub
DrugBank
DB01010
DrugBank Approved Drugs
DB01010
DrugCentral
988
DrugCentral Approved Drugs
988
DrugMAP
DMCRQHB
DrugMAP Approved Drugs
DMCRQHB
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
EOS101597
Guide to Pharmacology
9073
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1128
MedChem Express Bioactive Compound Library
HY-B0882
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
edrophonium-chloride
TargetMol Bioactive Compound Library
T5855
The Spectrum Collection
External IDs
58
Properties
(calculated by RDKit )
Molecular Weight
166.12
Hydrogen Bond Acceptors
1
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
1
Aromatic Ring Count
1
cLogP
1.98
TPSA
20.23
Fraction CSP3
0.4
Chiral centers
0.0
Largest ring
6.0
QED
0.67
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Acetylcholinesterase
Pathway
Neuroscience
Neuronal Signaling
Target
AChE
ACHE, BCHE
Cholinesterase (ChE)
AChR
Indication
myasthenia gravis
MOA
Acetylcholinesterase inhibitor
Therapeutic Class
Antidotes
Solubility
DMSO: 31 mg/mL
Source data